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Background: The small size of ultra-small nanoparticles makes them suitable for lymphatic delivery, and many
recent studies have examined their role in anti-metastasis therapy. However, the anti-metastatic efficacy of small-sized
nanocarriers loaded with taxanes such as docetaxel has not yet been investigated in malignant breast cancer.
Methods: We encapsulated docetaxel using poly(D,L-lactide)1300-b-(polyethylene glycol-methoxy)2000 (mPEG2000-b-
PDLLA1300) to construct polymeric micelles with a mean diameter of 16.76 nm (SPM). Patient-like 4T1/4T1
luc breast
cancer models in Balb/c mice, with resected and unresected primary tumors, were used to compare the therapeutic
efficacies of SPM and free docetaxel (Duopafei) against breast cancer metastasis using bioluminescent imaging, lung
nodule examination, and histological examination.
Result: SPM showed similar efficacy to Duopafei in terms of growth suppression of primary tumors, but greater
chemotherapeutic efficacy against breast cancer metastasis. In addition, lung tissue inflammation was decreased in the
SPM-treated group, while many tumor cells and neutrophils were found in the Duopafei-treated group.
Conclusion: Small-sized mPEG2000-b-PDLLA1300 micelles could provide an enhanced method of docetaxel delivery in
breast cancer metastasis, and may represent a valid chemotherapeutic strategy in breast cancer patients with resected
primary tumors.
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Primary tumor resectedBackground
Metastasis is the main cause of breast cancer (BC)-related
deaths [1]. Chemotherapy is currently used to prevent post-
operative recurrence and metastasis and to prolong patient
survival [2]. Nanotechnology has recently been acknow-
ledged as a breakthrough in drug-delivery systems, and
nanoparticles have emerged as promising carriers for anti-
cancer drug delivery [3]. To date, over 20 nanoparticle the-
rapeutics have been approved by the FDA for clinical use
[4,5]. However, nanotechnology chemotherapy for cancer
metastasis still presents a unique challenge, and has so far* Correspondence: zggao@imm.ac.cn
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unless otherwise stated.shown limited success. Increasing evidence suggests that
the regulation of primary tumor growth differs from that of
metastatic growth, and questions the clinical validity of
using traditional, large-sized nanodrug systems. Doxil and
Abraxane have provided only modest survival benefits be-
cause their large size hinders their delivery throughout the
tumor [6-9], and single-use Doxil and Abraxane proved in-
efficient against BC metastasis [10,11]. Most current nano-
therapeutic strategies focus on eliminating primary tumors
based on enhanced penetration and retention (EPR) in
well-vascularized primary tumors [12]. However, small me-
tastases are usually poorly-vascularized and are not well-
accessed by nanoparticles via the EPR effect, which is lim-
ited to tumors >4.8 mm in diameter, thus hindering the use
of these nanoparticles for targeting small and poorly-
vascularized metastases [13]. Generally, metastases presenthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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persion to organs, and lower vascularization than primary
tumors, making them less accessible to molecular and
nanoparticle agents [14].
Malignant BC cells metastasize via the circulation system.
Sentinel lymph nodes are typically the first site reached by
disseminating malignant cancer cells, and are thus associ-
ated with an increased risk of distant metastasis and poor
clinical outcome [15]. Although the primary tumor and af-
fected lymph nodes can be removed by surgery, tumor cells
remain inside the lymphatic vessels [16-18]. Preventing or
inhibiting lymph node metastasis is thus critical for im-
proving the outcome of BC patients, and the role of the
lymphatic system as a major conduit for the prolifera-
tion and spread of pathologies, including metastatic BC
[16-18], has directed attention on suitable drug-delivery
strategies. Smaller nanodrugs (10–30 nm diameter) have
recently proven effective against tumor metastasis and
their mechanisms can be explained by lymphatic accu-
mulation of these small-sized nanodrugs [19-22].
Transportation of agents by nanocarriers depends largely
on agent structures [23], and these small-sized nanocarriers
have been found to be suitable for incorporating water-
soluble anthracyclines or platinum agents because of their
electrostatic interactions and hydrophobic forces, but have
not been shown to be suitable for hydrophobic taxanes (e.g.
paclitaxel and docetaxel (DTX)) [19-22,24]. However,
taxanes demonstrate a high level of clinical activity, rep-
resented by clinical remissions in advanced ovarian,
breast and the upper aerodigestive tract cancers [25-27].
The central role of taxanes in the therapy of common
epithelial cancers is further highlighted by their ability
to induce remissions in patients with anthracycline- or
cis-platinum-resistant epithelial cancers [27,28]. DTX,
in particular, is broadly indicated for the treatment of
non-small cell lung cancer, and breast, prostate, stomach
and head and neck cancers [29], though these results re-
main open to debate [30], and is clinically preferred to
paclitaxel [29]. However, to our best of our knowledge,
very few studies have tested the efficacy of small-sized
nanoparticles to deliver DTX in metastatic BC models,
and the development of a small (10–30 nm) nanocarrier
for DTX is desperately needed.
The safety of poly(D,L-lactide)-b-polyethylene glycol-
methoxy(mPEG-b-PDLLA) mPEG-b-PDLLA-based poly-
meric micelles makes them one of the best delivery
systems for small molecule anti-cancer drugs [31-34].
mPEG2000-b-PDLLA1300 in particular has been shown
to be a good vehicle for taxanes, characterized by good
physical stability [35,36]. In this study, we used mPEG2000-
b-PDLLA1300 to prepare small-sized polymeric micelles
encapsulating DTX (SPM), and subsequently evaluated
their anti-metastatic efficiency in the highly-metastatic
4T1 mouse mammary tumor model. This tumor modelrecapitulates several features of advanced human BC,
including the ability to generate spontaneous lung and
lymph nodes metastases, and may be advocated as the
model most closely representing the clinical situation in
human cancer [37,38]. We compared the efficacy of
SPM with free DTX (Duopafei) as a positive control.
The therapeutic potential of SPM against metastasis was
evaluated using bioluminescent imaging, lung tumor
nodule examination, and histological examination.
Methods
Materials, cell line and animals
All reagents and solvents were used as received, without
further purification. Monomethoxy polyethylene glycol
with a molecular weight of 2000 Da (mPEG2000), D,L-
lactide, and stannous octoate were purchased from
Sigma-Aldrich Chemical Corp. (Shanghai, China); DTX
was purchased from Beijing Norzer Pharmaceutical Co.,
Ltd. (China); free DTX (Duopafei) was manufactured by
Qilu Pharm Co., Ltd. (Jinan, China); and 3-(4,5)-dimethyl-
thiazol(−z-y1)-3,5-di-phenytetrazoliumromide (MTT) was
obtained from Amresco (USA). Trypsin, fetal bovine
serum (FBS) and RPMI-1640 medium were purchased
from Hyclone (USA) and culture flasks and dishes were
from Corning (USA). The 4T1 murine mammary adeno-
carcinoma cell line was kindly provided by Prof. Wei
Liang of the Institute of Biophysics, Chinese Academy of
Sciences. The 4T1luc strain, which was genetically mani-
pulated to overexpress the firefly luciferase gene, was previ-
ously engineered in our lab by Prof. Wei Huang. 4T1 and
4T1luc cells were cultured in RPMI 1640 medium supple-
mented with 10% heat-inactivated FBS and incubated in a
humidified atmosphere of 5% CO2 and 95% air at 37°C.
Female Balb/c mice (6–8-weeks old) were used for an-
titumor efficacy studies and were purchased from Beijing
Vital River Laboratories (China). Animals were acclima-
tized in the holding facility prior to beginning the study.
All animal procedures were approved by the Institu-
tional Animal Care and Use Committee of the Chinese
Academy of Medical Sciences. All surgeries were per-
formed under sodium pentobarbital anesthesia (5 mg/
mL solution), and all efforts were made to minimize suf-
fering. Lung and liver sections were routinely stained
with hematoxylin-eosin (HE) and evaluated under a light
microscope.
Synthesis of mPEG2000-b-PDLLA1300
mPEG2000-b-PDLLA1300 was synthesized by the ring-
opening polymerization of D,L-lactide in the presence
of mPEG2000 homopolymer and a catalyst, as described
previously [35,36]. The molecular weights of copoly-
mers were characterized by nuclear magnetic reso-
nance (NMR) analysis using CDCl3 and a Mercury-400
spectrometer (Varian).
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encapsulating DTX
SPM was prepared by the conventional thin-film hydra-
tion method. Briefly, DTX (11.7 μmol) and mPEG2000-b-
PDLLA1300 (15.2 μmol) were dissolved in acetonitrile
(1 mL) in a round-bottomed flask to obtain a clear solu-
tion. The solvent was evaporated by rotary evaporation
at 60°C for 1 h to obtain a solid DTX/copolymer matrix.
Residual acetonitrile remaining in the film was removed
under vacuum overnight at room temperature. The re-
sultant thin film was hydrated with water at 60°C for
30 min to obtain a micelle solution.
SPM was extruded through a sterile membrane with
pore size 220 nm (Millipore) to remove unincorporated
DTX aggregates, and the sample was then diluted with
distilled water to yield a final DTX concentration of
1 mg/mL, as determined by high-performance liquid
chromatography (HPLC, Agilent 1200 series) with a
pentafluorophenyl column (Curosil-PFP, 4.6 × 250 mm,
5 μm, Phenomenex, Guangzhou, China). The mobile
phase was acetonitrile/water (50/50 (v/v)), and the flow
rate was set at 1.0 mL/min. Size distribution was investi-
gated by the dynamic light scattering (DLS) method
using Nano ZS90 (Malvern Instruments Inc.). The morph-
ology of SPM was characterized by transmission electron
microscopy (TEM, H-7650, Hitachi, Japan).
Loading capacity was defined as the percentage of
DTX by weight in the freeze-dried SPM, and encapsu-
lation efficiency was defined as the percentage of DTX
by weight incorporated in the micelles compared with the
initial weight of DTX. After filtering through a membrane
of pore size 220 nm, the SPM aqueous solution was
freeze-dried (Epslon 1–4 LSC, Chirst, Germany). The
loading amount of DTX was determined after dissol-
ving freeze-dried SPM in acetonitrile (1:10, w/v) to
completely destroy the core-shell structure of SPM.
The SPM aqueous solution was diluted in acetonitrile
(1:5, v/v) and the amount of DTX was then determined
using a calibration curve established from standard
solutions of DTX in acetonitrile by HPLC, using the
above method. Each experiment was carried out in
triplicate, and mean values ± standard deviations (SD)
were calculated using the following formulae: Loa-
ding capacity (w/w%) = [(amount of physically loaded
DTX)/(amount of SPM)] × 100%; Encapsulation effi-
ciency (w/w%) = [(amount of physically loaded DTX)/
(amount of DTX initially added)] × 100%.
The release profile of DTX from SPM was evaluated
using a dialysis membrane method: 0.5 mL of SPM so-
lution at a DTX concentration of 1 mg/mL was placed
in a dialysis bag (molecular mass cut-off 3.5 kDa). The
dialysis bag was incubated in 40 mL of phosphate-
buffered saline (PBS, pH 7.4) at 37°C with gentle sha-
king at 100 rpm, and aliquots of incubation mediumwere removed at predetermined time points. DTX in
the samples was quantified by HPLC using the above
method.
In vitro MTT cytotoxicity assay
The in vitro cytotoxicity was evaluated by MTT assay
using the murine mammary cancer cell line 4T1luc. Briefly,
cells were harvested from exponential-phase cultures,
counted, and plated in 96-well flat-bottomed microtiter
plates (5 × 103/well). After 24 h incubation for adherence,
cells were treated with a series of doses of Duopafei and
SPM, respectively. After 48 h incubation, 20 μL of MTT
(5 mg/mL) was added to each well of the plate followed
by incubation for an additional 4 h. The MTT was then
aspirated off and 200 μL/well of dimethyl sulfoxide was
added to dissolve the formazan crystals. Finally, the optical
density was measured at 490 nm using a microplate reader
(Synergy H1/H1 MF, Bio-Tek Inc.). Untreated cells were
used as control cells with 100% viability, and wells without
MTT were used as blanks to calibrate the spectropho-
tometer to zero absorbance. The results were expressed
as mean values ± SD of five measurements. The cell in-
hibition rate was calculated according to the formula:
Inhibition rate (%) = [1-(ODsample-ODblank)/(ODcontrol-
ODblank)] × 100%.
Cellular uptake of coumarin 6(C6)-loaded SPM (C6-SPM)
For in vitro fluorescence imaging, the near-infrared fluor-
escent probe C6 was loaded into mPEG2000-b-PDLLA1300
micelles to yield C6-SPM. Briefly, the polymers and excess
C6 were co-dissolved in CHCl3 and a thin film was
formed by the evaporation of CHCl3. PBS (pH 7.4) was
added, followed by vortexing for 10 min. The micelle sus-
pension was extruded through a sterile membrane of pore
size 220 nm (Millipore) to remove free C6.
4T1luc cells in exponential-stage growth were incu-
bated with C6-SPM at 37°C for 5, 10, 20, and 30 min, re-
spectively, rinsed three times with cold PBS, and then
fixed with 4% paraformaldehyde for 10 min. Finally, cells
were observed by confocal laser scanning microscopy
(CLSM, TCS SP2, Leica, Germany). Images were exam-
ined using differential interference contrast and C6-SPM
was recorded with the green channel (C6) with excita-
tion at 488 nm.
Cell apoptosis assay
Apoptotic cells were determined by dual staining with
an Annexin V and propidium iodide (PI) kit (China
KeyGEN Biosciences Company, China) according to
the manufacturer’s instructions. After 48 h of culture
in the exponential stage, 4T1luc cells seeded in 12-well
plates were treated for a further 48 h with 10 nmol/mL
Duopafei or SPM, respectively. After treatment, cells were
washed twice with warm PBS, detached by trypsin without
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resuspended in the binding buffer and further stained
with PI and Annexin V-FITC for 15 min at ambient
temperature in the dark. Apoptosis was then analyzed
using a FACScan cytometer equipped with Cell Quest
software (BD Biosciences, USA). Quadrant analysis was
performed and cells that stained positive for both
Annexin V-FITC and PI were designated as apoptotic,
while unstained cells were designated as live.
Chemotherapy in unresected advanced 4T1luc breast
carcinoma model
A cell suspension (0.1 mL) containing approximately
4 × 105 4T1luc cells at exponential stage was orthoto-
pically injected into a mammary gland in the lower right
quadrant of the abdomen of Balb/c female mice. Treatment
commenced when the primary tumor diameter reached
about 5–8 mm (day 9 after inoculation). The mice were di-
vided randomly into three equal groups (n = 10/group) for
treatment: negative control (5% glucose solution), Duopafei,
and SPM groups. Each treated group was injected intraven-
ously via the tail vein at a dose of 10 mg DTX/kg body
weight every 6 days for 24 days. Tumor volume (mm3) and
bodyweights were measured simultaneously. The expe-
riment was terminated at day 33 after inoculation.
Chemotherapy in unresected advanced 4T1luc breast
carcinoma model using bioluminescent method
Cell suspensions (0.1 mL) containing approximately 4 × 105
4T1luc cells at exponential stage were orthotopically
injected into a mammary gland in the lower right quadrant
of the abdomen of Balb/c female mice. Treatment com-
menced when the primary tumor diameter reached
about 6–8 mm (day 9 after inoculation). The mice were
divided randomly into two equal groups (n = 3/group)
for treatment: Duopafei and SPM groups. No negative
control group was established because the untreated
mice were very weak and unable to tolerate multiple
isoflurane anesthesia doses as a result of heavy lung
tumor burdens. Each treated group was injected intra-
venously via the tail vein at a dose of 10 mg DTX/kg
bodyweight every 6 days for 18 days. Anti-metastatic
activity was evaluated by bioluminescence imaging as
described above on days 9, 22, and 38 after inoculation.
In brief, mice were administered the substrate D-luciferin
(150 mg/kg in PBS) by intraperitoneal injection. Biolumin-
escence imaging was initiated 10 min after the injection.
Mice received continuous exposure to 1–2% isoflurane to
sustain sedation during imaging (IVIS-live Imaging
System 200, Xenogen, PerkinElmer, USA). The acquisi-
tion time was the same for all image collections (30 s)
and identical illumination settings were used for ac-
quiring all images. The experiment was terminated at
day 38 after inoculation. All mice were sacrificed andthe lungs were harvested, fixed in Bouin’s solution for
24 h, and then photographed.
Chemotherapy in unresected early-staged 4T1 breast
carcinoma model
Approximately 1 × 104 4T1 freshly prepared tumor cells
in exponential stage growth were injected into the lower
right quadrant of the abdomen of BALB/c female mice.
Treatment commenced when the primary tumor diam-
eter reached around 1–2 mm (day 14 after inoculation).
The mice were divided randomly into two equal groups
(n = 6/group) for treatment: Duopafei and SPM groups.
Each treated group was injected intravenously via the tail
vein at a dose of 10 mg DTX/kg body weight every
3 days for 12 days. The experiment was terminated at
day 26 after inoculation and all mice were sacrificed.
Lungs and livers were harvested and fixed in 4% formalin
solution for 72 h. The anti-metastatic efficacies of the treat-
ments were evaluated by HE staining of paraffin-embedded
tissues for histological examination of lungs and livers.
Stained sections were examined and photographed.
Postoperative chemotherapy in syngeneic murine 4T1luc
breast carcinoma model using bioluminescent method
Cell suspensions (0.1 mL) containing approximately 4 × 105
4T1luc cells in exponential-stage growth were injected
orthotopically into a mammary gland in the lower right
quadrant of the abdomen of BALB/c female mice. The
primary tumor was surgically removed when its diameter
reached about 6–8 mm (day 20 after inoculation), as de-
scribed previously [37,39]. Treatment commenced 7 days
after surgery (day 27 after inoculation). The mice were di-
vided randomly into three equal groups (n = 4/group) for
treatment: negative control (5% glucose solution), Duopafei
and SPM groups. Each treated group was injected intra-
venously via the tail vein at a dose of 5 mg DTX/kg body
weight every 7 days for 21 days, and mouse bodyweights
were measured simultaneously. Anti-metastatic activity
was evaluated by bioluminescence imaging at day 48
after inoculation, as described above. Experiments were
terminated at day 48 after inoculation. All mice were
sacrificed and the lungs were harvested, fixed in Bouin’s
solution for 24 h, and then photographed. The lungs
were then washed in PBS and put into 4% formalin solu-
tion for 72 h, dehydrated, and embedded in paraffin for
standard histological HE staining and photographing.
Statistical analysis
Data were described as means ± SD of the indicated num-
ber of individual experiments. If there was significant vari-
ation between treatment and control groups, the mean
values were compared using unpaired Student’s t-tests
to assess the statistical significance of the differences. A
P value of less than 0.05 was considered statistically
Li et al. BMC Cancer 2014, 14:329 Page 5 of 15
http://www.biomedcentral.com/1471-2407/14/329significant, and a P value of less than 0.01 was consid-
ered highly statistically significant.
Results
Preparation and characterization of micelles
mPEG2000-b-PDLLA1300 was successfully synthesized
according to the scheme in Figure 1A. The degree of
polymerization of PDLLA was calculated by comparing the
integral intensity of the characteristic resonance of PDLLA
at 5.2 ppm (−C(O)–CH(−CH3–)) and PEG resonance at
3.64 ppm (−OCH2CH2–) in the
1H NMR spectrum (as
shown in Figure 1B). The calculated result indicated a mean
molecular weight for mPEG-b-PDLLA of 3300 Da.
DTX was incorporated into SPM using the self-
assembly procedure (Figure 1C). The DTX-loading and ef-
ficiency into the micelles were 15.57 ± 0.73% and 97.7 ±
1.03%, respectively. The sizes were examined by DLS. As
shown in Figure 1D, SPM had a unimodal size distribution
with a mean diameter of 16.76 nm, which was within the
small-sized diameter range. TEM images showed that
SPM was monodisperse and spherical and the TEM aver-
age size was determined as 13.77 nm (Figure 1E). The
in vitro release behavior of SPM presented as the cumula-
tive percentage release is shown in Figure 1F. The afore-
mentioned polymer-metal complex formation between
DACHPt and the carboxylic group of the P(Glu) in the
PEG-b-P(Glu) led to the formation of polymeric micelles
with the average diameters of approximately 30 nm [21],Figure 1 Preparation and characterization of SPM. (A) Synthesis scheme
(C) Schematic illustration of SPM. (D) Size distribution of SPM in aqueous mediu
(F) In vitro release profile of SPM in PBS (pH 7.4).while doxorubicin and vinorelbine can be tightly pack-
aged into small-sized PEG-PE-based micelles due to the
amphiphilic nature of the drugs and PEG-PE molecules
and their specific structures [20]. The ability of a micelle
system to function as a solubilizer or a true carrier de-
pends on its stability and the diversity of polymer chem-
istry can provide a custom fit to drug molecules to be
loaded [23]. mPEG2000-b-PDLLA1300 was characterized
as a good, small-sized carrier for DTX (Figure 1), given
both the strong Van der Waals forces between the drug
and the inner core of the micelles and the intermolecu-
lar H-bond between the hydroxyl and amide groups of
DTX with the oxygen atoms in the PDLLA1300 chain,
which were proposed to contribute to the structural sta-
bility of the micelles.
In vitro cytotoxicity assays
We determined if encapsulation of DTX in SPM would
increase drug entry into tumor cells and cytotoxicity
in vitro. No blank micelle group was used in the MTT
study because the amphiphilic copolymer mPEG-b-
PDLLA has shown promising safety as a drug-delivery
material in many FDA-approved clinical trials [31,33,34].
4T1luc cells were exposed to a series of equivalent con-
centrations of Duopafei and SPM for 48 h, and the in-
hibition rates were quantified using the MTT method.
Tumor cell viabilities after 48 h incubation as a function
of the amount of DTX in Duopafei and SPM demonstratedfor mPEG2000-b-PDLLA1300. (B)
1H NMR spectra of mPEG2000-b-PDLLA1300.
m measured by DLS analysis. (E) TEM images of SPM. (Scale bar: 50 nm).
Figure 2 In vitro characterization of SPM. (A) Cytotoxic effects of Duopafei and SPM in 4T1luc cells, assessed by MTT assay. **P < 0.05. (B) CLSM
images of 4T1luc cells incubated with SPM for 5, 10, 20, and 30 min, respectively. (Scale bar: 37.5 μm). (C) Flow cytometry detected cell apoptosis
in 4T1luc cells incubated for 48 h with 10 nmol/mL Duopafei and SPM, respectively.
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mPEG2000-b-PDLLA1300 encapsulation accelerated cel-
lular uptake of the drug and induced higher cytotoxicity in
cancer cells, especially at lower DTX concentrations (0.1–
20 nmol/mL). At DTX concentrations of 10–20 nmol/mL,
the cytotoxicity of SPM was highly significantly greater
than that of Duopafei (P < 0.01), indicating favorable
in vivo drug delivery. However, 4T1luc cells were more
sensitive to Duopafei than SPM at higher concen-
trations (50–100 nmol/mL). Micelles are internalized
into cancer cells via endocytic mechanisms [40], while
the free drug diffuses into cells according to the
concentration gradient between the intracellular and
extracellular environments, explaining why Duopafei
is more cytotoxic at higher concentrations. These
results indicate that encapsulation of DTX in mPEG2000-Figure 3 Primary tumor-volume and bodyweight changes in Duopafeb-PDLLA1300 may significantly enhance the drug’s
cytotoxicity.
In vitro cellular uptake of SPM
Cellular uptake plays a key role in the nanodrug delivery
system. Poor cellular uptake may result in low levels of
intracellular DTX, ultimately leading to unsatisfactory
therapeutic effects. Cellular uptake of C6-SPM was quali-
tatively visualized by CLSM and the internalization speed
was roughly estimated. The CLSM images of 4T1luc cells
after incubation with C6-SPM for 5, 10, 20, and 30 min
are shown in Figure 2B. CLSM images at 5 and 10 min
showed that C6-SPM fluorescence (green) was closely lo-
cated around the membrane, indicating that C6-SPM had
not been internalized into 4T1luc cells. However, when the
incubation time was extended to 20 min, C6-SPM wasi- and SPM-treated mice bearing 4T1luc tumors.
Figure 4 Effects of SPM and Duopafei on cancer cell dissemination following primary 4T1luc tumor resection. (A) In vivo bioluminescent
images of Duopafei- or SPM-treated mice bearing 4T1luc tumors. Two mice in the Duopafei-treated group had died of metastases by day 38 after
inoculation. (B) Primary tumor and lung metastasis progression in the Duopafei- and SPM-treated groups were quantitatively monitored at day 38
after inoculation using biophotonic imaging analysis. M/P Ratio represents the ratio of luciferase activity in lung metastases to that in the
primary tumor.
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viously been reported to be internalized into the cytoplasm
together with the entrapped drug via an endocytic mecha-
nism [40], which process is demonstrated in Figure 2B.
SPM increased DTX-induced apoptosis in 4T1luc cells
DTX has beenwas described as anthe antimitotic agent
that binds to β-tubulin, resulting in block of the cell
cycle block at the G2/M phase and apoptosis of cells
[27,29]. E, enncapsulation of DTX in nanoparticles could
induce moreincreased apoptosis inof prostate cancer
cells through the activation of the caspase-2 pathway
[41].Given that SPM demonstrated stronger in vitro
cytotoxicity than free DTX, we performed apoptosis as-
says using Annexin V-FITC and PI staining to compare
apoptosis induction by SPM and Duopafei. As predicted,
SPM increased late apoptosis in 4T1luc cells compared
with Duopafei (25.38% vs 15.75%) (Figure 2C).Figure 5 Lung histology in the Duopafei- and SPM- treated groups. L
the metastatic nodule on the lung.Primary tumor inhibition by SPM and Duopafei in vivo
Nanoparticles can spontaneously extravasate and accu-
mulate in the tumor interstitium by the EPR effect as a
result of the unique fenestrated vascular architecture
and poor lymphatic drainage [3,13]. We investigated if
incorporation of DTX into micelles could improve their
efficacy against primary tumors in the same way. The
mean primary tumor volumes on day 33 after treatment
with Duopafei or SPM were 1300–1400 mm3, compared
with up to 2600 mm3 in the negative control group
(Figure 3). However, tumor growth in Duopafei-treated
mice was slower than in SPM-treated mice, though the
difference was not significant. All 4T1 tumors, regardless
of their size, are highly vascularized [37]. These results
suggest that SPM did not exert an EPR advantage against
primary tumors compared with Duopafei. Concerning the
bodyweight curve, SPM-treated mice lost less bodyweight
than Duopafei-treated mice, but the difference was notungs were immersed in Bouin’s fixative for 24 h. Red arrow indicates
Figure 6 Representative histopathological images of lungs from Duopafei-treated mice. 1, 2, 3, 4, 5 and 6 indicate individual mice (n = 6)
bearing 4Tl primary tumors with a diameter of 1–2 mm. (Scale bar: 200 μm).
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the body associated with the development of metastases.
SPM thus failed to demonstrate significant superiority
to Duopafei in terms of suppressing primary tumor
growth.
SPM prevents lung metastasis in advanced unresected BC
animal model
4T1luc cells express luciferase to visualize the metastasis
foci. Bioluminescence imaging can therefore be used to
provide a simultaneous and sensitive analysis of multiple
tissues/organs and to evaluate the anti-metastatic effica-
cies of agents [42,43]. We compared the anti-metastatic
abilities of SPM and Duopafei in unresected BC in 4T1luc
mice using bioluminescence imaging and metastatic nod-
ule examination (Figures 4 and 5). The results of longitu-
dinal imaging of the thoracic region and lower limbs at 9,
22 and 38 days after inoculation are shown in Figure 4. At
Day 38, the primary tumors generally reached ≥1 cm3 and
metastasis to the thoracic region was apparent in some
mice. The relative level of bioluminescence correlates with
the cancer burden [43]. As demonstrated in Figure 4A,
two mice were dead at day 38 after inoculation and onlyone mouse survived in the Duopafei-treated group, but
heavy lung metastasis was indicated by strong luciferase
activity in the thoracic region. In contrast, all the mice in
the SPM-treated group survived and only one showed
strong luciferase activity in the thoracic region.
To validate the bioluminescence results in Figure 4A,
lung foci were apparent as white nodules following
immersion of the lungs in Bouin’s fixative for 24 h. The
number of tumor nodules was taken as an indicator of
varying metastasis in a previous study of tumor cell
colonization in the lungs [20]. However, it cannot re-
flect the metastatic situation in the lung adequately be-
cause of differences in tumor nodule sizes; i.e., lungs
with more but smaller nodules do not necessarily indi-
cate more advanced metastasis than lungs with fewer
but larger metastatic nodules. We therefore used pho-
tographs to reflect lung metastasis development more
accurately. As shown in Figure 5, many large metastatic
nodules were found in one mouse in the Duopafei-treated
group and one mouse in the SPM-treated group, resulting
in strong luciferase activity (Figure 4A). However, one
mouse lung had three small metastatic nodules (indicated
by red arrows in Figure 5), which differed slightly from the
Figure 7 Representative histopathological images of lungs from SPM-treated mice. 1, 2, 3, 4, 5 and 6 indicate individual mice (n = 6)
bearing 4Tl primary tumors with a diameter of 1–2 mm. (Scale bar: 200 μm).
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http://www.biomedcentral.com/1471-2407/14/329bioluminescence imaging result in Figure 4A. This dis-
crepancy may be associated with limitations of the bio-
luminescence method, given that the fewer photons
generated by smaller metastatic lesions are less easily
detected by the device. Bioluminescence imaging was
performed using the Xenogen In Vivo Imaging System,
which consists of a supersensitive cooled charge-coupled
device camera mounted inside a light-tight imaging cham-
ber. However, the camera is only capable of detecting aFigure 8 Representative lung image from Duopafei-treated mouse. H
adjacent to blood vessels. Many identifiable neutrophils located extravascu
right scale bar: 100 μm).minimum radiance of 100 photons per second per square
centimeter per steridian [44], and the luciferase signals of
small metastatic foci usually disappear when imaged to-
gether with large primary tumors with much stronger
luciferase activity.
Lung metastasis surveillance was performed both visu-
ally (Figure 4A) and quantitatively by bioluminescence
(Figure 4B). As shown in Figure 4B, although there were
fewer absolute metastatic tumor cells in the Duopafei-E-stained lung from mouse no.1 showing metastatic cancer cells
larly were also observed in the lung tissue. (Left scale bar: 200 μm;
Figure 9 Representative liver images from Duopafei-treated mice. 1, 2, 3, 4, 5 and 6 indicate individual mice (n = 6) bearing 4Tl primary
tumors with a diameter of 1–2 mm. Red arrows indicate metastatic foci in the liver. (Scale bar: 200 μm).
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http://www.biomedcentral.com/1471-2407/14/329treated mouse compared with SPM-treated mice, the ratio
between the primary tumor and lung metastases was
much higher in the Duopafei- than in the SPM-treated
group. The 4T1luc primary tumor has been shown to play
an important role in promoting metastatic proliferation
[39], and these results suggest that SPM could suppress
metastatic proliferation from the primary tumor more effi-
ciently than Duopafei.
SPM suppresses lung and liver metastases in early-stage
unresected BC animal model
SPM was shown above to decrease the formation of lung
metastases in mice with advanced BC. 4T1 primary tu-
mors >3–4 mm in diameter that have been in place for
2 weeks are similar to advanced human BC [37]. We
also assessed the ability of SPM to reduce metastasis in
early-stage malignant BC. We inoculated as few as 1 ×
104 4T1 cells into the mammary fat pad of Balb/c mice,
sacrificed all mice when the primary tumors reached 1–
2 mm in diameter, and then evaluated metastasis deve-
lopment in the lung and liver by HE staining (Figures 6and 7). Given that inflammatory processes are known to
be involved in metastasis [17,42], we evaluated leukocyte
infiltration in the lung, as well as tumor cell metastasis.
Lung tissue from SPM-treated mice showed barely
measurable levels of tumor cells (Figure 7) and few neu-
trophils infiltrated by tumor cells. In contrast, many
tumor cells and neutrophils were found in close prox-
imity to vessels (Figures 6 and 8). The protumoral effect
of chronic inflammation has been extensively studied.
The tumor microenvironment contains many resident
cell types, such as adipocytes and fibroblasts, but is also
populated by migratory hematopoietic cells, most not-
ably macrophages, neutrophils and mast cells, which
play pivotal roles in the progression and metastasis of
tumors [17,42,45]. Fewer leukocytes, especially neutro-
phils, may have had an indirectly favorable effect on
lung metastasis in the SPM-treated group. We also
compared the HE results of liver metastases (Figures 9
and 10). Extensive metastases were found in the livers
of all mice, but mice treated with SPM showed fewer
liver metastases than those treated with Duopafei. Overall,
Figure 10 Representative liver images from SPM-treated mice. 1, 2, 3, 4, 5 and 6 indicate individual mice (n = 6) bearing 4Tl primary tumors
with a diameter of 1–2 mm. Red arrows indicate metastatic foci in the liver. (Scale bar: 200 μm).
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http://www.biomedcentral.com/1471-2407/14/329these results suggest that SPM could suppress metastases
in distant organs such as the lungs and liver in early-stage
malignant BC.
SPM suppresses metastasis in a postoperative
chemotherapy BC animal model
To simulate the real clinical situation, we examined
the anti-metastatic efficacy of SPM in a postoperative
model of the 4T1luc mammary tumor. Mice were inoc-
ulated orthotopically with 4T1luc cells in the fourth
mammary pad and the primary tumors were allowed to
grow progressively, become extensively vascularized,
and to metastasize. The primary tumors were then sur-
gically resected when their sizes reached 6–8 mm (day
20 after inoculation) and chemotherapy was initiated
(Additional file 1). To ensure the recovery of all mice,
chemotherapy began from the seventh day after sur-
gery (day 27 after inoculation).Bioluminescent images of mice treated with 5% glucose
solution (negative control) or different DTX formulations
are shown in Figure 11A. By day 48 after inoculation,
SPM-treated mice showed better metastasis control
with less luciferase activity compared with Duopafei,
which showed modest anti-metastatic effects (Figure 11B).
In addition to bioluminescence imaging, lung metastatic
nodules were photographed and examined following
immersion in Bouin’s fixative for 24 h. Two small
metastatic nodules were found in the lung of one
mouse in the SPM-treated group, while larger tumor
nodules were found in two mice in the Duopafei-
treated group, indicating more severe metastasis in the
latter group (Figure 12). The results of nodule examin-
ation differed slightly from the bioluminescence im-
aging results for the reasons discussed above. However,
metastases in mice treated with SPM were dramatically
decreased, whereas free DTX treatment only slightly
Figure 11 Effects of SPM and Duopafei on metastasis burden in resected 4T1luc chemotherapy animal model. (A) In vivo bioluminescent
images of mice (n = 4) after treatment with 5% glucose solution (negative control), Duopafei, or SPM. (B) Metastases progression was monitored
quantitatively in the Duopafei- and SPM-treated groups at day 49 after inoculation using biophotonic imaging analysis. (C) Bodyweight changes
in mice treated with 5% glucose solution (negative control), Duopafei, and SPM. Significant bodyweight loss was observed in the Duopafei-treated group
compared with the SPM-treated group (P < 0.05). (D) Representative histopathological images of lungs in the 5% glucose solution (negative control),
Duopafei- and SPM-treated groups. (Scale bar: 20 μm).
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http://www.biomedcentral.com/1471-2407/14/329reduced metastasis development. Surgical removal of
the primary tumors has the advantage of reflecting
the clinical situation where the primary breast tumor
is surgically removed and the metastatic foci remain
intact [46,47], and these results therefore provide
valuable information for clinical application.
Compared with the negative control group, SPM-
treated mice showed no bodyweight loss while Duopafei-
treated mice showed significant bodyweight loss (P < 0.05)
on day 49 after inoculation (Figure 11C). There were
no significant changes in gross measurements such as
skin ulceration, toxic death, behavior, or feeding in the
SPM-treated group. It is possible that SPM’s stability
prevented random DTX release into the body, while
its small size enhanced its anti-metastatic efficacy.
As reported in previous studies [17,42,45] and as dis-
cussed above, inflammation is believed to be associated
with cancer metastasis. In the present study, his-
tological evidence (Figure 11D) showed concomitant
anti-inflammatory activity in the lungs of SPM-treated
mice in accordance with Figures 6, 7 and 8. Whole-
lung HE images in mice with/without primary tumor
resection indicated that SPM could control metastasis
development more efficiently than free DTX.Discussion
Syngeneic murine models of metastatic BC are imperative
for testing new therapeutics in a preclinical setting. Highly-
malignant 4T1 mammary carcinoma cells, originally iso-
lated by Miller and colleagues, provides the most popular
spontaneous BC model [1,46]. In contrast to other expe-
rimental animal models in which tumor growth and pro-
gression do not parallel their human counterparts, many
characteristics of 4T1 tumors in syngeneic mice resemble
those of human mammary carcinomas, making the 4T1
model suitable for studies of metastatic cancer [1,42,48,49].
Moreover, 4T1 tumors are deemed to be one of the best
transplantable BC models in current use [38].
In this study, we prepared SPM, an mPEG2000-b-
PDLLA1300-based DTX polymeric micelle formulation
with a particle size (i.e., 10–30 nm) previously shown
to result in maximal accumulation in lymph nodes
[20,21]. Compared with free DTX (Duopafei), SPM was
more effective in inhibiting the growth of 4T1 tumor cells
in vitro by inducing late apoptosis. In animal models with
unresected primary tumors resected, SPM at a safe dosage
(10 mg DTX/kg body weight) remarkably inhibited BC
metastasis to distant major organs such as the lungs and
liver compared with Duopafei.
Figure 12 Histological images of lungs in Duopafei- and SPM-treated mice. Lungs were examined after immersion in Bouin’s fixative for
24 h in mice treated with 5% glucose solution (negative control), Duopafei or SPM. Red arrows indicatet metastatic foci on the lung.
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http://www.biomedcentral.com/1471-2407/14/329In most clinical situations, primary mammary tumors are
treated by surgery, but approximately 33% of women suc-
cessfully treated for primary tumors still die subsequently
from spontaneous metastatic disease [50]. Primary 4T1 tu-
mors can readily be removed surgically, allowing metastatic
disease to be studied in an animal setting comparable
to the clinical situation [37]. In animal models with
resected primary tumors, SPM demonstrated greater
inhibition of 4T1luc cell dissemination and fewer signsof toxicity compared with Duopafei. Previous studies
have reported differences in the effectiveness and tox-
icities of micelle-encapsulated drugs [19-24], indicat-
ing that the choice of nanocarrier is critical, and that
cancer therapies based on polymeric micelles can im-
prove drug efficacy without increasing the drug dose,
and while also reducing systemic toxicity. The present
results validated SPM as an effective future treatment
for preventing the metastasis of malignant BC.
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http://www.biomedcentral.com/1471-2407/14/329The lymph nodes are typically the first site reached
by disseminating malignant BC cells, correlated with
an increased risk of distant metastasis and poor clinical
outcome [15]. Although the primary tumor and affected
lymph nodes can be removed during surgery, tumor
cells remain inside the lymphatic vessels [16-18]. SPM
did not outperform Duopafei in terms of suppressing
growth of the primary tumor [39], but dramatically
suppressed metastasis, especially in mice with resected
primary tumors. The enhanced anti-metastatic efficacy
of SPM may be attributed to its lymphatic accumula-
tion associated with its small size and increased deli-
very to the lymphatic system, which is consistent with
previous observations using other kinds of anti-cancer
drugs [19-22,24].
Many solid tumors, including breast tumors, are associ-
ated with local inflammation [51]. Indeed, cancer-related
inflammation has recently been proposed as the seventh
hallmark of cancer [52]. A previous study of 4T1 tumors
observed a progressive increase in hematopoiesis through-
out the 6-week time course as primary tumors progressed
and metastases developed at distant sites [42]. This was fur-
ther evidenced by increasing levels of circulating neutro-
phils and the development of inflammation in the lungs in
the present study. The decreased inflammation in the lungs
in the SPM-treated group confirmed that SPM slowed the
development of metastases in the lung and other distant
major organs.
The present study had some limitations. Despite consi-
derable progress in demonstrating the anti-metastatic
effects of SPM against malignant BC, the molecular basis
underlying its inhibitory functions remains obscure and
further experiments are needed to address this issue.
Conclusions
In conclusion, SPM encapsulating DTX showed greater
anti-metastatic efficacy than Duopafei in the clinically
relevant BC spontaneously metastatic mouse model. To
the best of our knowledge, this is the first study to in-
vestigate the use of DTX and mPEG2000-b-PDLLA1300
as a small-sized drug-delivery system for preventing the
metastasis of malignant BC. The particle size of SPM is
suitable for blocking the lymph node pathway during
the cancer cell dissemination process. As an alternative
to free DTX, SPM may show reduced toxicity and im-
proved anti-metastatic efficacy. The results of this study
indicate that SPM represents a promising clinical ap-
proach for treating metastatic disease associated with
malignant BC.Additional file
Additional file 1: Surgical removal of the primary tumor.Abbreviations
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